Skip to content

Study · Not a test of the peptide alone · 2000

1 result

Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.

Hedlund PO, Henriksson P

Urology1 Mar 2000Cited by 47 (Europe PMC)

PMID10699602 (opens in a new tab)DOI10.1016/s0090-4295(99)00580-4 (opens in a new tab)PepBankPUB-10699602
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome

    In advanced prostate cancer, overall survival did not differ between triptorelin plus flutamide and orchiectomy within the androgen-ablation group.

    In plain wordsIn advanced prostate cancer, survival did not differ between triptorelin plus flutamide and orchiectomy.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeOverall survival
    Study

    n: not reported in source

    Comparator
    Orchiectomy
    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    Within the TAA group, no difference in overall survival existed between patients who had undergone orchiectomy or who were given triptorelin.
    2 context sentences
    Summary · context
    Nine hundred fifteen patients were randomized to intramuscular injections of 240 mg polyestradiol phosphate (PEP) every second week for the first 8 weeks (5 doses) followed by a maintenance dose of 240 mg every month (n = 458) or to bilateral orchiectomy or triptorelin 3.75 mg every month combined w…
    Summary · context
    The choice between orchiectomy and triptorelin was at the discretion of the clinician and patient.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.